References
- Teahon K, Smethurst P, Macpherson AJ, Levi J, Menzies IS, Bjamason I. Intestinal permeability in Crohn’s disease and its relation to disease activity and relapse following treatment with elemental diet. Eur J Gastroenterol Hepatol 1993;5:79–84.
- Ukabam SO, Clamp JR, Cooper BT. Abnormal small intestinal permeability to sugars in patients with Crohn’s disease of the terminal ileum and colon. Digestion 1983;27:70–4.
- Anton PA, Targan SR, Shanahan F. Increased neutrophil receptors for and response to the proinflammatory bacterial peptide formyl-methionyl-leucyl-phenylalanine in Crohn’s disease. Gastroenterology 1989;97:20–8.
- Riehl TE, Stenson WF. Mechanisms of transit of lipid mediators of inflammation and bacterial peptides across intestinal epithelia. Am J Physiol Gastrointest Liver Physiol 1994;267: 687–95.
- Yamada T, Sartor RB, Marshall S, Specian RD, Grisham MB. Mucosal injury and inflammation in a model of chronic granulomatous colitis in rats. Gastroenterology 1993;104:759–71.
- Wyatt J, Vogelsang H, Hübl W, Waldhöer T, Lochs H. Intestinal permeability and the prediction of relapse in Crohn’s disease. Lancet 1993;341:1437–9.
- Hilsden RJ, Meddings JB, Hardin J, Gall DG, Sutherland LR. Intestinal permeability and postheparin plasma diamine oxidase activity in the prediction of Crohn’s disease relapse. Inflammatory Bowel Diseases 1999;5:85–91.
- Meddings JB. Intestinal permeability in Crohn’s disease. Aliment Pharmacol Ther 1997;11:47–56.
- Laker MF, Bull HJ, Menzies IS. Evaluation of mannitol for use as a probe marker of gastrointestinal permeability in man. Eur J Clin Invest 1982;12:485–91.
- Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, et al. European Cooperative Crohn’s Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984;86: 249–66.
- Bjarnason I, MacPherson A, Hollander D. Intestinal permability: an overview. Gastroenterology 1995;108:1566–81.
- Kirsner JB, Shorter RG. Recent developments in nonspecific inflammatory bowel disease. N Engl J Med 1982;306:837–48.
- Shorter RG, Huizenga KA, Spencer RJ. A working hypothesis for the etiology and pathogenesis of nonspecific inflammatory bowel disease. Dig Dis 1972;17:1024–32.
- Katz KD, Hollander D, Vadheim CM, McElree C, Delahunty T, Dadufalza VD, et al. Intestinal permeability in patients with Crohn’s disease and their healthy relatives. Gastroenterology 1989;97:927–31.
- Munkholm P, Langholz E, Hollander D, Thornberg K, Orholm M, Katz KD, et al. Intestinal permeability in patients with Crohn’s disease and ulcerative colitis and their first-degree relatives. Gut 1994;35:68–72. 51
- Bjarnason I, O’Morain C, Levi AJ, Peters TJ. Absorption of 51-chromium-labeled ethylenediaminetetraacetate in inflammatory bowel disease. Gastroenterology 1983;85:318–22.
- Ainsworth M, Eriksen J, Rasmussen JW, Schaffalitzky de Muckadell OB. Intestinal permeability of 51Cr-labelled ethyle-nediaminetetraacetic acid in patients with Crohn’s disease and their healthy relatives. Scand J Gastroenterol 1989;24: 993–8.
- Jenkins AP, Nukajam WS, Menzies IS, Creamer B. Simultaneous administration of lactulose and 51Cr-ethylenediaminete-traacetic acid. A test to distinguish colonic from small-intestinal permeability change. Scand J Gastroenterol 1992;27:769–73.
- Elia M, Behrens R, Northrop C, Wraight P, Neale G. Evaluation of mannitol, lactulose and 51Cr-labelled ethylenediaminetetraa-cetate as markers of intestinal permeability in man. Clin Sci 1987;73: 197–204.
- Hilsden RJ, Meddings JB, Sutherland LR. Intestinal permeability changes in response to acetylsalicylic acid in relatives of patients with Crohn’s disease. Gastroenterology 1996;110: 1395–403.
- May GR, Sutherland LR, Meddings JB. Is small intestinal permeability really increased in relatives of patients with Crohn’s disease? Gastroenterology 1993;104:1627–32.